ELAN ELANCO ANIMAL HEALTH INC revenue, earnings and financials
For the quarter ended June 30, 2026, ELANCO ANIMAL HEALTH INC reported revenue of $1.37B (up 10.2% from a year earlier), net income of $54.0M and diluted EPS of $0.11; over the last four quarters revenue was $5.02B and net income −$199M; for the fiscal year ended December 2025 revenue was $4.72B, up 6.2% on the year before.
ELAN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $4.72B, gross profit $2.59B, operating income n/a, net income −$232M (margin -4.9%), EPS −$0.47
- Fiscal year ended Dec 2024: revenue $4.44B, gross profit $2.44B, operating income n/a, net income $338M (margin 7.6%), EPS $0.68
- Fiscal year ended Dec 2023: revenue $4.42B, gross profit $2.49B, operating income n/a, net income −$1.23B (margin -27.9%), EPS −$2.50
- Fiscal year ended Dec 2022: revenue $4.41B, gross profit n/a, operating income n/a, net income −$78.0M (margin -1.8%), EPS −$0.16
- Fiscal year ended Dec 2021: revenue $4.76B, gross profit n/a, operating income n/a, net income −$483M (margin -10.1%), EPS −$0.99
ELAN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.37B (up 10.2% year over year), net income $54.0M, EPS $0.11
- Quarter ended Mar 31, 2026: revenue $1.37B (up 14.9% year over year), net income $57.0M, EPS $0.11
- Quarter ended Dec 31, 2025 (from the annual report): revenue $1.14B (up 12.2% year over year), net income −$276M, EPS −$0.55
- Quarter ended Sep 30, 2025: revenue $1.14B (up 10.4% year over year), net income −$34.0M, EPS −$0.07
- Quarter ended Jun 30, 2025: revenue $1.24B (up 4.8% year over year), net income $11.0M, EPS $0.02
- Quarter ended Mar 31, 2025: revenue $1.19B (down 1.0% year over year), net income $67.0M, EPS $0.13
- Quarter ended Dec 31, 2024 (from the annual report): revenue $1.02B (down 1.4% year over year), net income −$8.00M, EPS −$0.01
- Quarter ended Sep 30, 2024: revenue $1.03B (down 3.6% year over year), net income $364M, EPS $0.73
- Quarter ended Jun 30, 2024: revenue $1.18B (up 12.0% year over year), net income −$50.0M, EPS −$0.10
- Quarter ended Mar 31, 2024: revenue $1.21B (down 4.1% year over year), net income $32.0M, EPS $0.06
- Quarter ended Dec 31, 2023 (from the annual report): revenue $1.04B (up 5.2% year over year), net income −$141M, EPS −$0.29
- Quarter ended Sep 30, 2023: revenue $1.07B (up 4.1% year over year), net income −$1.10B, EPS −$2.22
- Quarter ended Jun 30, 2023: revenue $1.06B (down 10.0% year over year), net income −$97.0M, EPS −$0.20
- Quarter ended Mar 31, 2023: revenue $1.26B (up 2.5% year over year), net income $103M, EPS $0.21
- Quarter ended Dec 31, 2022 (from the annual report): revenue $984M (down 11.5% year over year), net income −$54.0M, EPS −$0.11
- Quarter ended Sep 30, 2022: revenue $1.03B (down 9.3% year over year), net income −$65.0M, EPS −$0.13
- Quarter ended Jun 30, 2022: revenue $1.18B (down 8.1% year over year), net income −$10.0M, EPS −$0.02
- Quarter ended Mar 31, 2022: revenue $1.23B (down 1.3% year over year), net income $51.0M, EPS $0.10
- Quarter ended Dec 31, 2021: revenue $1.11B, net income −$105M, EPS −$0.22
- Quarter ended Sep 30, 2021: revenue $1.13B, net income −$108M, EPS −$0.22
ELAN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $560M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $541M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow $271M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $452M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $483M, share buybacks n/a
ELAN balance sheet
- Jun 30, 2026: cash $530M, total assets $13.6B, total liabilities $6.97B, shareholders' equity $6.59B
- Mar 31, 2026: cash $428M, total assets $13.2B, total liabilities $6.72B, shareholders' equity $6.50B
- Dec 31, 2025: cash $545M, total assets $13.4B, total liabilities $6.81B, shareholders' equity $6.55B
- Sep 30, 2025: cash $505M, total assets $13.6B, total liabilities $6.80B, shareholders' equity $6.75B
- Jun 30, 2025: cash $539M, total assets $13.7B, total liabilities $6.97B, shareholders' equity $6.78B
- Mar 31, 2025: cash $487M, total assets $12.9B, total liabilities $6.59B, shareholders' equity $6.35B, long-term debt $4.35B
- Dec 31, 2024: cash $468M, total assets $12.6B, total liabilities $6.52B, shareholders' equity $6.10B, long-term debt $4.28B
- Sep 30, 2024: cash $490M, total assets $13.3B, total liabilities $6.76B, shareholders' equity $6.52B, long-term debt $4.31B
What is ELAN's revenue?
ELANCO ANIMAL HEALTH INC reported $5.02B of revenue over its last four quarters, through June 30, 2026.
Is ELAN profitable?
No. ELANCO ANIMAL HEALTH INC lost $199M over the last four quarters.
What is ELAN's EPS?
Diluted earnings per share over the last four quarters were −$0.40; $0.11 in the latest quarter.